Growth Metrics

Inhibikase Therapeutics (IKT) Total Non-Current Liabilities (2026)

Inhibikase Therapeutics (IKT) has 1 years of Total Non-Current Liabilities data on record, last reported at $5.3 million in Q1 2026.